eFFECTOR Therapeutics (EFTR) S-4/A 5 Aug 21 Registration of securities issued in business combination transactions (amended) Financial data

Cover Page

Cover Page	3 Months Ended
	Mar. 31, 2021
Document Information [Line Items]
Document Type	S-4/A
Amendment Flag	true
Amendment Description	Amendment No. 2
Entity Registrant Name	Locust Walk Acquisition Corp.
Entity Central Index Key	0001828522
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)		Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash		$ 1,467,723	$ 12,031
Prepaid expenses		344,648	0
Due from sponsor		625
Total Current Assets		1,812,996	12,031
Marketable securities held in Trust Account		175,003,740	0
Deferred offering costs		0	177,937
TOTAL ASSETS		176,816,736	189,968
Current liabilities
Accounts payable and accrued expenses		240,998	758
Accrued offering costs		0	105,841
Promissory note – related party		0	60,375
Total Current Liabilities		240,998	166,974
Warrant liabilities		3,674,600	0
Deferred underwriting fee payable		6,565,000	0
Total Liabilities		10,480,598	166,974
Commitments and Contingencies
Class A common stock subject to possible redemption, $10.00 per shares redemption value; 16,133,613 and no shares as of March 31, 2021 and December 31, 2020, respectively		161,336,130	0
Stockholders' Equity
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding		0	0
Additional paid-in capital		4,952,534	24,546
Retained earnings (accumulated deficit)		46,831	(2,006)
Total Stockholders' Equity		5,000,008	22,994
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		176,816,736	189,968
Class A Common stock
Stockholders' Equity
Common stock		191	0
Class B Common Stock
Stockholders' Equity
Common stock	[1]	$ 452	$ 454	[2],[3]
[1]	As of December 31, 2020, shares included up to 573,750 shares of Class B common stock subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters. Due to the underwriter’s partial exercise of the over-allotment option on January 11, 2021, the Sponsor (as defined below) forfeited 23,750 shares of Class B common stock, resulting in 4,511,250 Founder Shares (as defined below) outstanding as of March 31, 2021.
[2]	Includes up to 573,750 shares of Class B common stock subject to forfeiture if the overallotment option is not exercised in full or in part by the underwriters. Due to the underwriter’s partial exercise of the over-allotment on January 11, 2021, the Sponsor forfeited 23,750 shares of Class B common stock resulting in 4,511,250 Founder Shares outstanding.
[3]	The Company effected a stock dividend on January 7, 2021 of 1.17259212 shares of Class B common stock for each share of Class B common stock outstanding prior to the dividend, resulting in an aggregate of 4,535,000 shares of Class B common stock outstanding. All share and per share amounts have been retroactively restated to reflect the stock dividend (see Note 5).

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class A Common stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	1,911,387	0
Common stock, shares outstanding	1,911,387	0
Temporary equity shares outstanding	16,133,613	0
Temporary equity, redemption price per share	$ 10	$ 10
Class B Common Stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	4,511,250	4,535,000
Common stock, shares outstanding	4,511,250	4,535,000
Number of shares forfeited during the period		573,750
Common stock dividend		1.17259212
Class B Common Stock | Founder Shares
Temporary equity shares outstanding	4,511,250	4,511,250
Class B Common Stock | Sponsor
Number of shares forfeited during the period	23,750	23,750

Condensed Statement of Operatio

Condensed Statement of Operations - USD ($)		3 Months Ended
		Mar. 31, 2021	Dec. 31, 2020
Operations and formation costs
Formation and operating costs			$ 2,006
Operational costs		$ 318,012
Franchise tax		50,758
Total operations and formation costs		368,770
Loss from operations		(368,770)
Other income (expense):
Interest earned on marketable securities held in Trust Account		3,740
Transaction costs incurred in connection with warrant liabilities		(242,333)
Change in fair value of warrant liability		656,200
Other income		417,607
Net income (loss)		$ 48,837	$ (2,006)
Weighted average shares outstanding	[1],[2]		3,961,250
Basic and diluted net income/loss per share			$ 0
Class A redeemable Common Stock [Member]
Other income (expense):
Weighted average shares outstanding		17,500,000
Basic and diluted net income/loss per share		$ 0
Class A And Class B Non Redeemable Common Stock [Member]
Other income (expense):
Weighted average shares outstanding	[3]	4,922,417
Basic and diluted net income/loss per share		$ 0.01
[1]	Excludes up to 573,750 shares of Class B common stock subject to forfeiture if the overallotment option is not exercised in full or in part by the underwriters. Due to the underwriter’s partial exercise of the over-allotment on January 11, 2021, the Sponsor forfeited 23,750 shares of Class B common stock resulting in 4,511,250 Founder Shares outstanding.
[2]	The Company effected a stock dividend on January 7, 2021 of 1.17259212 shares of Class B common stock for each share of Class B common stock outstanding prior to the dividend, resulting in an aggregate of 4,535,000 shares of Class B common stock outstanding. All share and per share amounts have been retroactively restated to reflect the stock dividend (see Note 5).
[3]	As of December 31, 2020, shares included up to 573,750 shares of Class B common stock subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters. Due to the underwriter’s partial exercise of the over-allotment option on January 11, 2021, the Sponsor forfeited 23,750 shares of Class B common stock, resulting in 4,511,250 Founder Shares outstanding as of March 31, 2021. These shares were excluded from the calculation of weighted average shares outstanding until they were no longer subject to forfeiture. If forfeited, they have been excluded from the calculation of weighted average shares outstanding.

Condensed Statement of Operat_2

Condensed Statement of Operations (Parenthetical) - Class B Common Stock - shares	Mar. 31, 2021	Jan. 11, 2021	Jan. 07, 2021	Dec. 31, 2020	Oct. 31, 2020
Number of shares forfeited during the period				573,750
Common stock dividend			1.17259212	1.17259212
Common stock, shares outstanding	4,511,250		4,535,000	4,535,000
Founder Shares
Temporary equity shares outstanding	4,511,250	4,511,250		4,511,250
Sponsor
Number of shares forfeited during the period	23,750	23,750		23,750
Sponsor | Founder Shares
Temporary equity shares outstanding					4,511,250

Condensed Statement of Changes

Condensed Statement of Changes in Stockholders' Equity - USD ($)		Total	Common StockClass A Common Stock	Common StockClass B Common Stock		Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)
Beginning Balance at Oct. 01, 2020
Beginning Balance (shares) at Oct. 01, 2020
Sale of 545,000 Placement Units	[1],[2]	25,000		$ 454		24,546
Sale of 545,000 Placement Units (shares)	[1],[2]			4,535,000
Net income (loss)		(2,006)					(2,006)
Ending Balance at Dec. 31, 2020		22,994		$ 454	[3]	24,546	(2,006)
Ending Balance (shares) at Dec. 31, 2020	[3]			4,535,000
Sale of 17,500,000 Units, net of underwriting discounts, initial value of public warrants and other offering costs		160,945,107	$ 1,750			160,943,357
Sale of 17,500,000 Units, net of underwriting discounts, initial value of public warrants and other offering costs (shares)			17,500,000
Sale of 545,000 Placement Units		5,319,200	$ 55			5,319,145
Sale of 545,000 Placement Units (shares)			545,000
Forfeiture of Founder Shares				$ (2)	[3]	2
Forfeiture of Founder Shares (shares)	[3]			(23,750)
Class A Common stock subject to possible redemption		(161,336,130)	$ (1,614)			(161,334,516)
Class A Common stock subject to possible redemption (shares)			(16,133,613)
Net income (loss)		48,837					48,837
Ending Balance at Mar. 31, 2021		$ 5,000,008	$ 191	$ 452	[3]	$ 4,952,534	$ 46,831
Ending Balance (shares) at Mar. 31, 2021			1,911,387	4,511,250	[3]
[1]	Includes up to 573,750 shares of Class B common stock subject to forfeiture if the overallotment option is not exercised in full or in part by the underwriters. Due to the underwriter’s partial exercise of the over-allotment on January 11, 2021, the Sponsor forfeited 23,750 shares of Class B common stock resulting in 4,511,250 Founder Shares outstanding.
[2]	The Company effected a stock dividend on January 7, 2021 of 1.17259212 shares of Class B common stock for each share of Class B common stock outstanding prior to the dividend, resulting in an aggregate of 4,535,000 shares of Class B common stock outstanding. All share and per share amounts have been retroactively restated to reflect the stock dividend (see Note 5).
[3]	As of December 31, 2020, shares included up to 573,750 shares of Class B common stock subject to forfeiture if the over-allotment option was not exercised in full or in part by the underwriters. Due to the underwriter’s partial exercise of the over-allotment option on January 11, 2021, the Sponsor forfeited 23,750 shares of Class B common stock, resulting in 4,511,250 Founder Shares outstanding as of March 31, 2021.

Condensed Statement of Change_2

Condensed Statement of Changes in Stockholders' Equity (Parenthetical) - shares	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
IPO [Member]
Stock issued during period shares	15,300,000	15,300,000
IPO [Member] | Public Warrants
Stock issued during period shares	17,500,000
Private Placement [Member]
Stock issued during period, shares, issued for services	545,000
Class B Common Stock
Number of shares forfeited during the period		573,750
Common stock, shares outstanding	4,511,250	4,535,000
Common stock dividend		1.17259212
Class B Common Stock | Founder Shares
Temporary equity shares outstanding	4,511,250	4,511,250
Class B Common Stock | Sponsor
Number of shares forfeited during the period	23,750	23,750

Condensed Statement of Cash Flo

Condensed Statement of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net income (loss)	$ 48,837	$ (2,006)
Adjustments to reconcile net income to net cash used in operating activities:
Payment of formation costs through promissory note		175
Change in fair value of warrant liability	(656,200)
Transaction costs allocated to warrant liabilities	242,333
Interest earned on marketable securities held in Trust Account	(3,740)
Changes in operating assets and liabilities:
Accrued expenses		758
Prepaid expenses and other current assets	(344,648)
Accounts payable and accrued expenses	240,241
Net cash used in operating activities	(473,177)	(1,073)
Cash Flows from Investing Activities:
Investment into trust account	(175,000,000)
Net cash used in investing activities	(175,000,000)
Cash Flows from Financing Activities
Proceeds from sale of Units, net of underwriting discounts paid	171,940,000
Proceeds from sale of Placement Units	5,450,000
Proceeds from promissory note — related party		55,000
Repayment of promissory note – related party	(61,000)
Payment of offering costs	(400,131)	(66,896)
Net cash provided by financing activities	176,928,869	13,104
Net Change in Cash	1,455,692	12,031
Cash – Beginning of period	12,031
Cash – End of period	1,467,723	12,031
Non-cash investing and financing activities:
Deferred underwriting fee payable	6,565,000
Initial classification of common stock subject to possible redemption	161,045,270
Forfeiture of Founder Shares	(2)
Change in value of common stock subject to possible redemption	$ 290,860
Deferred offering costs included in accrued offering costs		105,841
Deferred offering costs paid through promissory note - related party		5,200
Class B Common Stock
Cash Flows from Financing Activities
Proceeds from issuance of Class B common stock to Sponsor		$ 25,000

Description of Organization And

Description of Organization And Business Operations	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Organization and Business Operations	NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Locust Walk Acquisition Corp. (the “Company”) is a blank check company incorporated in Delaware on October 2, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business transaction with one or more operating businesses or assets (a “Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of March 31, 2021, the Company had not yet commenced operations. All activity through March 31, 2021 relates to the Company’s formation, its initial public offering (the “IPO”), which is described below and, subsequent to the IPO, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating On May 26, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Locust Walk Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of the Company (“Merger Sub”), and eFFECTOR Therapeutics, Inc., a Delaware corporation (“eFFECTOR”). For more information, see the “Merger” described below. The registration statement for the Company’s IPO was declared effective on January 12, 2021. On January 12, 2021, the Company consummated the IPO of 17,500,000 units (the “Units” and, with respect to the Class A common stock included in the Units sold, the “Public Shares”), which includes the partial exercise by the underwriter of its over-allotment option in the amount of 2,200,000 Units, at $10.00 per Unit, generating gross proceeds of $175,000,000 4 Simultaneously with the closing of the IPO, the Company consummated the sale of 545,000 units (the “Placement Units”) at a price of $10.00 per Placement Unit in a private placement to Locust Walk Sponsor, LLC (the “Sponsor”), that closed simultaneously with the IPO, generating gross proceeds of $5,450,000 (Note 5 Transaction costs amounted to $10,097,226, consisting of $3,060,000 in cash underwriting fees, $6,565,000 of deferred underwriting fees and $472,226 of other offering costs. Following the closing of the IPO, $175,000,000 was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 2a-7 months from the consummation of the IPO (the “Combination Period”); or (iii) the distribution of the Trust Account, as described below, except that interest earned on the Trust Account can be released to pay the Company’s tax obligations, if the Company is unable to complete an initial Business Combination within the Combination Period or upon any earlier liquidation of the Company. The Company’s management has broad discretion with respect to the specific application of the net proceeds from the IPO, although substantially all of the net proceeds are intended to be applied toward consummating a Business Combination. There is no assurance that the Company will be able to successfully effect a Business Combination. Rules of the Nasdaq Capital Market (“Nasdaq”) provide that the Company must complete a Business Combination with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of signing a definitive agreement in connection with a Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company will provide stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made solely by the Company. The stockholders will be entitled to redeem their Public Shares for a pro rata 7 The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor and the Company’s officers and directors (together with the Sponsor, the “Insiders”) have agreed to vote their Founder Shares (Note 6), the shares of Class A common stock included in the Placement Units (the “Placement Shares”) and any Public Shares held by them in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. The Company will also provide stockholders with the opportunity to redeem all or a portion of their Public Shares in connection with any stockholder vote to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of Public Shares if it does not complete an initial Business Combination within the Combination Period. Stockholders will be entitled to redeem their shares for a pro rata pro rata 7 The Company will have until the expiration of the Combination Period to consummate its initial Business Combination. If the Company is unable to consummate a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including any interest earned on the Trust Account not previously released to the Company to pay its tax obligations and up to $100,000 of interest to pay dissolution expenses, divided by the number of then outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and; (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. The Insiders have agreed to waive their redemption rights with respect to any Founder Shares and Placement Shares, as applicable, (i) in connection with the consummation of a Business Combination, (ii) in connection with a stockholder vote to amend its Amended and Restated Certificate of Incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if it does not complete its initial Business Combination within the Combination Period, and (iii) if the Company fails to consummate a Business Combination within the Combination Period. The Insiders have also agreed to waive their redemption rights with respect to any Public Shares held by them in connection with the consummation of a Business Combination and in connection with a stockholder vote to amend its Amended and Restated Certificate of Incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if it does not complete its initial Business Combination within the Combination Period. However, the Insiders will be entitled to redemption rights with respect to Public Shares if the Company fails to consummate a Business Combination or liquidates within the Combination Period. The representative has agreed to waive its rights to deferred underwriting commissions held in the Trust Account in the event the Company does not consummate a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the initial public offering price per Unit in the IPO. Placing funds in the Trust Account may not protect those funds from third-party claims against the Company. Although the Company will seek to have all vendors, service providers (except our independent registered public accounting firm), prospective target businesses or other entities it engages, execute agreements with the Company waiving any claim of any kind in or to any monies held in the Trust Account, there is no guarantee that such persons will execute such agreements. The Sponsor has agreed that it will be liable under certain circumstances to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or vendors or other entities that are owed money by the Company for service rendered, contracted for or products sold to the Company. However, it may not be able to satisfy those obligations should they arise. Notwithstanding the foregoing redemption rights, if the Company seeks stockholder approval of its Business Combination and it does not conduct redemptions in connection with its Business Combination pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to an aggregate of 20.0% or more of the shares sold in the IPO. However, there is no restriction on the Company’s stockholders’ ability to vote all of their shares for or against a Business Combination. The Merger On May 26, 2021, the Company entered into the Merger Agreement by and among the Company, Merger Sub, a Delaware corporation and a wholly-owned subsidiary of the Company, and eFFECTOR. Pursuant to the Merger Agreement, at the closing of the transactions contemplated thereby (the “Closing”), Merger Sub will merge with and into eFFECTOR (the “Merger”) with eFFECTOR surviving the Merger as a wholly-owned subsidiary of the Company. In addition, in connection with the consummation of the Merger, the Company will be renamed “eFFECTOR Therapeutics, Inc.” At the effective time of the Merger (the “Effective Time”), by virtue of the consummation of the Merger and without any further action on the part of the Company, Merger Sub or eFFECTOR (after eFFECTOR causes each share of eFFECTOR preferred stock that is issued and outstanding immediately prior to the consummation of the Merger to be automatically converted immediately prior to the consummation of the Merger into a number of shares of eFFECTOR common stock at the then-effective conversation rate as calculated in accordance with eFFECTOR’s organizational documents and after eFFECTOR causes each outstanding warrant to purchase shares of eFFECTOR capital stock to be exercised in full on a cash or cashless basis or terminated without exercise), each share of eFFECTOR common stock issued and outstanding immediately prior to the Effective Time shall be canceled and automatically converted into the right to receive a number of shares of the Company’s common stock as calculated based on the Exchange Ratio (as defined below) and a number of Earn-Out Shares (as defined below) as set forth in the Merger Agreement. “Exchange Ratio” is defined in the Merger Agreement to be 34,000,000 divided by the number of shares of fully diluted eFFECTOR capital stock (which equals the outstanding shares of eFFECTOR common stock and options to purchase shares of eFFECTOR common stock as of immediately prior to the Effective Time, after giving effect to the conversion of the eFFECTOR preferred stock and exercise of the eFFECTOR warrants and as further adjusted pursuant to the Merger Agreement). At the Effective Time, each outstanding option to purchase shares of eFFECTOR common stock will be converted into an option to purchase shares of the Company’s common stock equal to the number of shares subject to such option prior to the Effective Time multiplied by the Exchange Ratio, with the per-share exercise price equal to the exercise price prior to the Effective Time divided by the Exchange Ratio. Following the Closing, former holders of shares of eFFECTOR common stock (including shares received as a result of the conversion of eFFECTOR preferred stock and exercise of the eFFECTOR warrants) and eFFECTOR stock options will be entitled to receive their pro rata The Merger Agreement contains customary representations and warranties of the parties thereto with respect to, among other things, (a) entity organization, good standing and qualification, (b) capital structure, (c) authorization to enter into the Merger Agreement, (d) compliance with laws and permits, (e) financial statements and internal controls, (f) absence of certain changes and undisclosed liabilities, (g) litigation, (h) labor and employee matters, (i) environmental matters, (j) tax matters, (k) real and personal property, (l) intellectual property, (m) insurance, (n) material contracts, (o) brokers and finders, (p) regulatory compliance and (q) transactions with affiliates. The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, covenants providing for the Company and eFFECTOR to use reasonable best efforts to cooperate in the preparation of the Registration Statement and Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of their respective stockholders including, in the case of the Company, approvals of the Merger Agreement and the Merger, the restated certificate of incorporation, the share issuance under the rules of Nasdaq and the incentive award plan and employee stock purchase plan of the combined company. The Closing is subject to certain customary conditions of the respective parties, including, among other things, (i) receipt of the Company’s stockholder approval and eFFECTOR stockholder approval, (ii) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (iii) the absence of any governmental order, statute, rule or regulation enjoining or prohibiting the consummation of the transactions contemplated by the Merger Agreement, (iv) the effectiveness of the Registration Statement (as defined in the Merger Agreement) under the Securities Act of 1933, as amended (the “Securities Act”), (v) the Company having at least $5,000,001 of net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act), (vi) the common stock of the combined company to be issued pursuant to the Merger Agreement being listed or having been approved for listing on Nasdaq, (vii) the consummation of the private placement financing concurrent with the Closing, (viii) solely with respect to the Company, (A) the representations and warranties of eFFECTOR being true and correct to applicable standards in the Merger Agreement and each of the covenants of eFFECTOR having been performed or complied with in all material respects, (B) since the date of the Merger Agreement there not having been a material adverse effect on eFFECTOR that is continuing and (C) the approval of the settlement of the eFFECTOR warrants pursuant to the terms of such warrants and such settlement of the eFFECTOR warrants having been consummated and (ix) solely with respect to eFFECTOR, (A) the representations and warranties of the Company being true and correct to applicable standards in the Merger Agreement and each of the covenants of the Company having been performed or complied with in all material respects, (B) since the date of the Merger Agreement there not having been a material adverse effect on the Company that is continuing, (C) the effective resignations of certain directors and executive officers of the Company, and (D) the amount of Closing Parent Cash (as defined in the Merger Agreement) being equal to or exceeding $100,000,000. In connection with the execution of the Merger Agreement, the Company entered into subscription agreements (collectively, the “Subscription Agreements”) with certain parties subscribing for shares of the Company’s common stock (the “Subscribers”), pursuant to which the Subscribers have agreed to purchase, and the Company has agreed to sell to the Subscribers, an aggregate of 6,000,000 shares of the Company’s common Stock, for a purchase price of $10.00 per share, resulting in an aggregate purchase price of $60,000,000 (the “PIPE Financing”). The obligations to consummate the transactions contemplated by the Subscription Agreements are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Merger Agreement. In connection with the Merger, the Company plans to file with the SEC a Registration Statement on Form S-4, that includes a preliminary proxy statement/prospectus, and, when available, the Company intends to file a definitive proxy statement and final prospectus to call a special meeting of the holders of the Company common stock to vote at the meeting (the “Special Meeting”). The holders of the majority of the voting power of the Company’s common stock present in person or represented by proxy at the Special Meeting must approve the Merger Agreement, the Merger and certain other actions related thereto, as provided in the Delaware General Corporation Law, the Company’s Amended and Restated Certificate of Incorporation and applicable listing rules of Nasdaq. The Merger Agreement may be terminated by the Company or eFFECTOR under certain circumstances, including (i) by mutual written consent of the Company and eFFECTOR; (ii) by either the Company or eFFECTOR if the Closing has not occurred on or before November 26, 2021; or (iii) by either the Company or eFFECTOR if the Company has not obtained the necessary stockholder approvals. The Merger Agreement, Subscription Agreements and other support agreements have been filed as exhibits to and described in the Company’s Current Report on Form 8-K filed with the SEC on May 27, 2021.	NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS Locust Walk Acquisition Corp. (the “Company”) is a blank check company incorporated in Delaware on October 2, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business transaction with one or more operating businesses or assets (a “Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of December 31, 2020, the Company had not commenced operations. All activity for the period from October 2, 2020 (inception) through December 31, 2020 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”). The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating On January 12, 2021, the Company consummated the IPO of 17,500,000 units (the “Units” and, with respect to the Class A common stock included in the Units sold, the “Public Shares”), which includes the partial exercise by the underwriter of its over-allotment option in the amount of 2,200,000 Units, at $10.00 per Unit, resulting in gross proceeds of $175,000,000. Simultaneously with the closing of the IPO, the Company consummated the sale of 545,000 units (the “Placement Units”) at a price of $10.00 per Placement Unit in a private placement to Locust Walk Acquisition Corp. (the “Sponsor”), that closed simultaneously with the IPO, generating gross proceeds of $5,450,000, which is described in Note 4. Transaction costs amounted to $10,097,226, consisting of $3,060,000 in current underwriting fees, $6,565,000 of deferred underwriting fees and $472,226 of other offering costs. Following the closing of the IPO, $175,000,000 of the net proceeds were placed in a trust account (the “Trust Account”) and was invested in U.S. government securities, until the earlier of: (i) the consummation of a Business Combination; (ii) the redemption of any Public Shares in connection with a stockholder vote to amend the Company’s Amended and Restated Certificate of Incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if it does not complete an initial Business Combination within 24 months from the consummation of the IPO or January 12, 2023 (the “Combination Period”); or (iii) the distribution of the Trust Account, as described below, except that interest earned on the Trust Account can be released to pay the Company’s tax obligations, if the Company is unable to complete an initial Business Combination within the Combination Period or upon any earlier liquidation of the Company. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and sale of the Placement Units, although substantially all of the net proceeds are intended to be applied toward consummating a Business Combination. There is no assurance that the Company will be able to successfully effect a Business Combination. Nasdaq rules provide that the Company must complete a Business Combination with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of signing a definitive agreement in connection with a Business Combination. The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company will provide its stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor and the Company’s officers and directors (together with the Sponsor, the “Insiders”) have agreed to vote their Founder Shares (as defined in Note 5), the shares of Class A common stock included in the Placement Units (the “Placement Shares”) and any Public Shares held by them in favor of approving a Business Combination. Additionally, each public stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. The Company will also provide its stockholders with the opportunity to redeem all or a portion of their Public Shares in connection with any stockholder vote to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of Public Shares if it does not complete an initial Business Combination within the Combination Period. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account, net of taxes payable). The per-share The Company will have until the expiration of the Combination Period to consummate its initial Business Combination. If the Company is unable to consummate a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share The Insiders have agreed to waive their redemption rights with respect to any Founder Shares and Placement Shares, as applicable, (i) in connection with the consummation of a Business Combination, (ii) in connection with a stockholder vote to amend the Company’s Amended and Restated Certificate of Incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if it does not complete its initial Business Combination within the Combination Period, and (iii) if the Company fails to consummate a Business Combination within the Combination Period. The Insiders have also agreed to waive their redemption rights with respect to any Public Shares held by them in connection with the consummation of a Business Combination and in connection with a stockholder vote to amend the Company’s Amended and Restated Certificate of Incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if it does not complete its initial Business Combination within the Combination Period. However, the Insiders will be entitled to redemption rights with respect to Public Shares if the Company fails to consummate a Business Combination or liquidates within the Combination Period. The representative has agreed to waive its rights to deferred underwriting commissions held in the Trust Account in the event the Company does not consummate a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than the initial public offering price per Unit in the Initial Public Offering. Placing funds in the Trust Account may not protect those funds from third party claims against the Company. Although the Company will seek to have all vendors, service providers (except our independent registered public accounting firm), prospective target businesses or other entities it engages, execute agreements with the Company waiving any claim of any kind in or to any monies held in the Trust Account, there is no guarantee that such persons will execute such agreements. Locust Walk Partners, LLC, has agreed that it will be liable under certain circumstances to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or vendors or other entities that are owed money by the Company for service rendered, contracted for or products sold to the Company. However, it may not be able to satisfy those obligations should they arise. Notwithstanding the foregoing redemption rights, if the Company seeks stockholder approval of its Business Combination and it does not conduct redemptions in connection with its Business Combination pursuant to the tender offer rules, the Amended and Restated Certificate of Incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to an aggregate of 20% or more of the shares sold in the IPO. However, there is no restriction on the Company’s stockholders’ ability to vote all of their shares for or against a Business Combination.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q S-X The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s prospectus for its IPO as filed with the SEC on January 7, 2021. The interim results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future periods. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging Use of Estimates The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liability. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2021 and December 31, 2020. Marketable Securities Held in Trust Account At March 31, 2021, substantially all of the assets held in the Trust Account were invested in Morgan Stanley’s Institution Liquid Treasury Securities Portfolio. The fund invests in U.S. Treasury obligation with maturities not to exceeding 397 Offering Costs Offering costs, consisting of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the IPO, amounting to approximately $9,800,000 were charged to stockholders’ equity upon the completion of the IPO. For the three months ended March 31, 2021, approximately $242,000 of costs are included in transaction costs incurred in connection with warrant liabilities in the unaudited condensed statement of operations. Class A Common Stock Subject to Possible Redemption The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s Class A common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at March 31, 2021, 16,133,613 shares of Class A common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the condensed balance sheet. Warrant Liability The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in non-cash are valued using a closed form Black-Scholes model. Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of March 31, 2021, the Company had a deferred tax asset of approximately $77,077, which had a full valuation allowance recorded against it The Company’s deferred tax assets were deemed to be de minimis Current taxable income primarily consists of interest earned on the Trust Account. The Company’s general and administrative costs are generally considered start-up start-up ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were The Company may be subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception. Net income per Share of Common Stock Net income per share is computed by dividing net income by the weighted average number of shares of common stock outstanding for the period. The Company has not considered the effect of warrants sold in the IPO and private placement to purchase 6,015,000 shares of Class A common stock in the calculation of diluted net income per share, since the exercise price of the warrants was above the average market price for the period. The condensed statement of operations includes a presentation of income per share of common stock subject to possible redemption in a manner similar to the two-class non-redeemable non-redeemable non-redeemable The following table reflects the calculation of basic and diluted net income per share of common stock (in dollars, except per share amounts): Three Months Ended March 31, 2021 Redeemable Class A Common Stock Numerator: Earnings allocable to Redeemable Class A common stock Interest income $ 3,740 Income and franchise tax (3,740 ) Net Income — Denominator: Weighted average Redeemable Class A common stock Redeemable Class A common stock, Basic and Diluted 17,500,000 Basic and diluted income per share, Class A redeemable common stock $ — Non-redeemable Numerator: Net Income minus redeemable net income Net income $ 48,837 Redeemable net income — Non-redeemable 48,837 Denominator: Weighted average Non-Redeemable Non-redeemable 4,922,417 Basic and diluted net income per share, Class A and Class B non-redeemable $ 0.01 Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, Fair Value Measurement, approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Recent Accounting Standards In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2020-06, 470-20) 815-40) 2020-06”) 2020-06 2020-06 if-converted 2020-06 2020-06	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2020. Deferred Offering Costs Deferred offering costs consisted of legal, accounting and other expenses incurred through the balance sheet date that were directly related to the IPO. On January 12, 2021, offering costs amounting to $10,097,226 were charged to stockholder’s equity upon the completion of the IPO (see Note 1). As of December 31, 2020, there were $177,937 of deferred offering costs recorded in the accompanying balance sheet. Income Taxes The Company complies with the accounting and reporting requirements of Accounting Standards Codification (“ASC”) Topic 740 “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not The Company may be subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception. The provision for income taxes was deemed to be de minimis for the period from October 2, 2020 (inception) through December 31, 2020. As of December 31, 2020, deferred taxes were de minimis. Net Loss Per Common Share Net loss per share of common stock is computed by dividing net loss by the weighted average number of common shares outstanding during the period, excluding shares of common stock subject to forfeiture. Weighted average shares were reduced for the effect of an aggregate of 573,750 shares of Class B common stock that are subject to forfeiture by the Sponsor if the over-allotment option is not exercised by the underwriter (see Note 5). At December 31, 2020, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the period presented. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation insurance limits of $250,000. The Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the Company’s balance sheet, primarily due to their short-term nature. Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statement	3 Months Ended
	Mar. 31, 2021
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Financial Statement	NOTE 3 — RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENT The Company previously accounted for its outstanding Public Warrants (Note 4) and Placement Warrants (collectively, with the Public Warrants, the “Warrants”) issued in connection with its IPO as components of equity instead of as derivative liabilities. The warrant agreement governing the Warrants (the “Warrant Agreement”) includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the Warrant. In addition, the Warrant Agreement includes a provision that in the event of a tender offer or exchange offer made to and accepted by holders of more than 50% of the outstanding shares of a single class of stock, all holders of the Warrants would be entitled to receive cash for their Warrants (the “tender offer provision”). On April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Statement”). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the Warrant Agreement. In further consideration of the SEC Statement, the Company’s management evaluated the Warrants under ASC Subtopic 815-40, Section 815-40-15 Section 815-40-15, Section 815-40-15 fixed-for-fixed Section 815-40-25. In accordance with ASC Topic 340, Other Assets and Deferred Costs, as a result of the classification of the Warrants as derivative liabilities, the Company expensed a portion of the offering costs originally recorded as a reduction in equity. The portion of offering costs that was expensed was determined based on the relative fair value of the Public Warrants and Class A common stock included in the Units. As a result of the above, the Company should have classified the Warrants as derivative liabilities in its previously issued financial statement as of January 12, 2021. Under this accounting treatment, the Company is required to measure the fair value of the Warrants at the end of each reporting period as well as re-evaluate The Company’s accounting for the Warrants as components of equity instead of as derivative liabilities did not have any effect on the previously reported investments held in trust or cash. As Previously Reported Restatement As Restated Balance sheet as of January 12, 2021 (audited) Warrant Liability – Public Warrants $ — $ 4,200,000 $ 4,200,000 Warrant Liability – Placement Warrants — 130,800 130,800 Total Warrant Liabilities — 4,330,800 4,330,800 Class A Common Stock Subject to Possible Redemption 165,376,070 (4,330,800 ) 161,045,270 Class A Common Stock 151 44 195 Additional Paid-in 5,001,101 242,289 5,243,390 Accumulated Deficit (1,698 ) (242,333 ) (244,031 ) Number of Class A Common Stock Subject to Possible Redemptio n 16,537,607 (433,080 ) 16,104,527

Public Offering

Public Offering	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Public Offering	NOTE 4. PUBLIC OFFERING Pursuant to the IPO, the Company sold Units, which includes a partial exercise by the underwriter of its over-allotment option in the amount of Units, at a purchase price of per Unit. Each Unit consists of one share of Class A common stock and one-third share of Class A common stock at an exercise price of (see Note 9).	NOTE 3 — INITIAL PUBLIC OFFERING Pursuant to the IPO, the Company sold 17,500,000 Units, which includes a partial exercise by the underwriter of their over-allotment option in the amount of 2,200,000 Units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and one-third

Private Placement

Private Placement	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Private Placement	NOTE 5. PRIVATE PLACEMENT Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 545,000 Placement Units at a price of $10.00 per Placement Unit, for $5,450,000. Each whole Placement Warrant is exercisable for one share of Class A common stock at a price of $11.50 per share. The proceeds from the Placement Units were added to the proceeds from the IPO held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Placement Units, including all underlying securities, will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Placement Units or its underlying securities.	NOTE 4 — PRIVATE PLACEMENT Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 545,000 Placement Units at a price of $10.00 per Placement Unit, or $5,450,000 in the aggregate, in a private placement. Each Placement Unit consists of one share of Class A common stock and one-third

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 6. RELATED PARTY TRANSACTIONS Founder Shares In October 2020, the Company issued an aggregate of 3,867,500 shares of Class B common stock to the Sponsor (the “Founder Shares”) for an aggregate purchase price of $25,000. The Company effected a stock dividend on January 7, 2021 of 1.17259212 shares of Class B common stock for each share of Class B common stock outstanding prior to the dividend and, as a result, the Sponsor held 4,535,000 Founder Shares. As a result of the underwriters’ election to only partially exercise their over-allotment option, the Sponsor forfeited 23,750 shares of Class B common stock resulting in 4,511,250 Founder Shares outstanding. In connection with the execution of the Merger Agreement, the Sponsor entered into a sponsor support agreement, dated as of May 26, 2021 (the “Sponsor Support Agreement”) with the Company and eFFECTOR, pursuant to which to which the Sponsor agreed to vote all of its shares of the Company’s common stock in favor of the Merger and that it would not sell, assign or otherwise transfer any of its shares of the Company’s common stock , subject to certain exceptions as permitted under the Sponsor Support Agreement. In connection with the execution of the Merger Agreement, the Sponsor also entered into a sponsor lock-up agreement, which shall become effective as of the Effective Time (the “Sponsor Lock-up Agreement”), with the Company, pursuant to which, subject to certain limited exceptions, the Sponsor has agreed not to transfer any of its shares of the Company’s common stock during the period beginning on the date of the Closing (the “Closing Date”) and ending on the earlier of (x) 270 days after the Closing Date, (y) the date on which the price of the Company’s common stock equals or exceeds $12.00 for any 20 trading days within any 30 trading day period following the 90th day after the Closing Date, and (z) a Change of Control (as defined in the Sponsor Lock-up Agreement). The transfer restrictions set forth in the Sponsor Support Agreement and the Sponsor Lock-up Agreement supersede and replace the transfer restrictions set forth in that certain letter agreement, dated January 7, 2021, between the Company, the Sponsor and the directors and officers of the Company. Administrative Services Agreement The Company entered into an agreement, commencing on January 12, 2021 through the earlier of the consummation of a Business Combination and its liquidation, to pay the Sponsor or an affiliate of the Sponsor $10,000 per month for office space, administrative and shared personnel support services. For the three months ended March 31, 2021, the Company incurred $15,015, of which such amount is included in accounts payable and accrued expenses in the accompanying March 31, 2021 condensed balance sheet. Promissory Note — Related Party On October 6, 2020, as amended on December 7, 2020, the Company issued a promissory note to the Sponsor, pursuant to which the Sponsor agreed to loan the Company up to aggregate of $300,000 to be used for the payment of costs related to the IPO (the “Promissory Note”). The Promissory Note was no bearing, outstanding under the Promissory Note, respectively. The Company overpaid the outstanding balance under the Promissory Note upon the closing of the IPO on January 1 9 Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor, members of the Company’s management team or any of their respective affiliates or other third parties may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”), which will be repaid only upon the consummation of a Business Combination. If the Company does not consummate a Business Combination, the Company may use a portion of any funds held outside the Trust Account to repay the Working Capital Loans; however, no proceeds from the Trust Account may be used for such repayment. If such funds are insufficient to repay the Working Capital Loans, the unpaid amounts would be forgiven. Up to $1,500,000 of the Working Capital Loans may be converted into units at a price of $10.00 per unit at the option of the holder. The units would be identical to the Placement Units. As of March 31, 2021 and December 31, 2020, there were no amounts outstanding under the Working Capital Loans.	NOTE 5 — RELATED PARTY TRANSACTIONS​​​​​​​ Founder Shares In October 2020, the Company issued an aggregate of 3,867,500 shares of Class B common stock to the Sponsor (the “Founder Shares”) for an aggregate purchase price of $25,000. The Company effected a stock dividend on January 7, 2021 of 1.17259212 shares of Class B common stock for each share of Class B common stock outstanding prior to the dividend and, as a result, the Sponsor held 4,535,000 Founder Shares. Due to the underwriter’s partial exercise of the over-allotment on January 11, 2021, the Sponsor forfeited 23,750 shares of Class B common stock resulting in 4,511,250 Founder Shares outstanding. All share and per-share amounts have been retroactively restated to reflect the stock dividend. The Insiders have agreed not to transfer, assign or sell any of their Founder Shares (except to permitted transferees) until (i) with respect to 25% of such shares, upon consummation of the Company’s initial Business Combination, (ii) with respect to 25% of such shares, when the closing price of the Class A common stock exceeds $12.00 for any 20 trading days within a 30-trading 30-trading 30-trading Administrative Services Agreement The Company entered into an agreement, commencing on January 12, 2021 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay the Sponsor or an affiliate of the Sponsor $10,000 per month for office space, administrative and shared personnel support services. Promissory Note — Related Party On October 6, 2020, as amended on December 7, 2020, the Company issued a promissory note to the Sponsor, pursuant to which the Sponsor agreed to loan the Company up to aggregate of $300,000 to be used for the payment of costs related to the Initial Public Offering (the “Promissory Note”). The Promissory Note is non-interest bearing, Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor, members of the Company’s management team or any of their respective affiliates or other third parties may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”), which will be repaid only upon the consummation of a Business Combination. If the Company does not consummate a Business Combination, the Company may use a portion of any funds held outside the Trust Account to repay the Working Capital Loans; however, no proceeds from the Trust Account may be used for such repayment. If such funds are insufficient to repay the Working Capital Loans, the unpaid amounts would be forgiven. Up to $1,500,000 of the Working Capital Loans may be converted into units at a price of $10.00 per unit at the option of the holder. The units would be identical to the Placement Units. As of December 31, 2020, there were no amounts outstanding under the Working Capital Loans.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 7. COMMITMENTS Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 Registration Rights Pursuant to a registration rights agreement entered into on January 7, 2021, the holders of the Founder Shares, Placement Units (including securities contained therein) and the warrants that may be issued upon conversion of the Working Capital Loans (and any shares of Class A common stock issuable upon the exercise of the Placement Warrants or the warrants issued upon conversion of the Working Capital Loans) will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to Class A common stock). The holders of these securities will be entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders will have “piggy-back” registration rights to include such securities in other registration statements filed by the Company and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. PIPE Financing In connection with the execution of the Merger Agreement, the Company entered into the Subscription Agreements with certain Subscribers, pursuant to which the Subscribers agreed to purchase, and the Company agreed to sell to the Subscribers, an aggregate of 6,000,000 shares of the Company’s common stock, for a purchase price of $10.00 per share, resulting in an aggregate purchase price of $60,000,000. For more information regarding the PIPE Financing, see the description of the Merger in Note 1 above. Underwriting Agreement As a result of the underwriter’s election to partially exercise the over-allotment option to purchase an additional 2,200,000 Units, 95,000 over-allotment option Units have been forfeited. The underwriter is entitled to a deferred underwriting fee of (i) 3.5% of the gross proceeds of the initial 15,300,000 Units sold in the Initial Public Offering, or $5,355,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the overallotment option, or $1,210,000. The deferred underwriting fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.	NOTE 6 — COMMITMENTS AND CONTINGENCIES Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 Registration Rights Pursuant to a registration rights agreement entered into on January 7, 2021, the holders of the Founder Shares, Placement Units (including securities contained therein) and the warrants that may be issued upon conversion of the Working Capital Loans (and any shares of Class A common stock issuable upon the exercise of the Placement Warrants or the warrants issued upon conversion of the Working Capital Loans) will be entitled to registration rights requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to Class A common stock). The holders of these securities will be entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders will have “piggy-back” registration rights to include such securities in other registration statements filed by the Company and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement As a result of, the underwriter’s election to partially exercise the over-allotment option to purchase an additional 2,200,000 95,000 The underwriter is entitled to a deferred underwriting fee of (i) 3.5 5,355,000 5.5 1,210,000

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Stockholders' Equity	NOTE 8. STOCKHOLDERS’ EQUITY Preferred Stock — Class A Common Stock Class B Common Stock shares of Class B common stock were forfeited as a result of the underwriter’s election to partially exercise its over-allotment option, so that the number of Founder Shares would equal 20% of the Company’s issued and outstanding common stock after the IPO. Holders of Class B common stock will vote on the election of directors prior to the consummation of a Business Combination. Holders of Class A common stock and Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders except as required by law. Shares of Class B common stock will automatically convert into shares of Class A common stock at the time of a Business Combination on a one-for-one as-converted	NOTE 7 — STOCKHOLDER’S EQUITY Preferred Stock 1,000,000 0.0001 no Class A Common Stock 100,000,000 0.0001 Holders of Class A common stock are entitled to one vote for each share. no Class B Common Stock 10,000,000 0.0001 Holders of the Company’s Class B common stock are entitled to one vote for each common share. 4,535,000 23,750 20 Holders of Class B common stock will vote on the election of directors prior to the consummation of a Business Combination. Holders of Class A common stock and Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders except as required by law. The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of a Business Combination on a one-for-one as-converted Warrants no The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise for cash of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue shares of Class A common stock upon exercise of a warrant unless Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt from the registration or qualifications requirements of the securities laws of the state of residence of the registered holder of the warrants. Notwithstanding the foregoing, if a registration statement covering the shares of Class A common stock issuable upon exercise of the Public Warrants has not been declared effective by the end of 60 business days following the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act. The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of a Business Combination, the Company will use its reasonable best efforts to file with the SEC, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, the Company will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Once the warrants become exercisable, the Company may redeem the Public Warrants: • in whole and not in part; • at a price of $0.01 per warrant; • upon not less than 30 days’ prior written notice of redemption to each warrant holder; and • if, and only if, the reported last sale price of the Company’s Class A common stock (or the closing bid price of the common stock in the event shares of common stock are not traded on any specific day) equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption for cash, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless. In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by the Company and in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Insiders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 50% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the completion of a Business Combination (net of redemptions), and (z) the volume-weighted average trading price of the shares of Class A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company completes a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. The Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Placement Warrants and the Class A common stock issuable upon the exercise of the Placement Warrants will not be transferable, assignable or saleable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Placement Warrants will be non-redeemable

Warrants

Warrants	3 Months Ended
	Mar. 31, 2021
Warrants and Rights Note Disclosure [Abstract]
Warrants	NOTE 9. WARRANTS Warrants months from the closing of the IPO. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise for cash of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue shares of Class A common stock upon exercise of a warrant unless Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt from the registration or qualifications requirements of the securities laws of the state of residence of the registered holder of the warrants. Notwithstanding the foregoing, if a registration statement covering the shares of Class A common stock issuable upon exercise of the Public Warrants has not been declared effective by the end of 60 business days following the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act. The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of a Business Combination, the Company will use its reasonable best efforts to file with the SEC, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the Warrants and to maintain a current prospectus relating to those shares of Class A common stock until the Warrants expire or are redeemed, as specified in the Warrant Agreement. If a registration statement covering the shares of Class A common stock issuable upon exercise of the Warrants is not effective by the 60th business day after the closing of a Business Combination, Warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise the Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, the Company will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Once the Warrants become exercisable, the Company may redeem the Public Warrants: • in whole and not in part; • at a price of $0.01 per W • upon not less than 30 days prior written notice of redemption; and • if, and only if, the reported last sale price of the Company’s Class A common stock (or the closing bid price of the common stock in the event shares of common stock are not traded on any specific day) equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading day period ending three business days before the Company sends the notice of redemption to the Warrant holders. If and when the Warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption for cash, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the Warrant Agreement. The exercise price and number of shares of Class A common stock issuable upon exercise of the Warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. Additionally, in no event will the Company be required to net cash settle the Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Warrants will not receive any of such funds with respect to their Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Warrants. Accordingly, the Warrants may expire worthless. In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by the Company and in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Insiders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 50% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the completion of a Business Combination (net of redemptions), and (z) the volume-weighted average trading price of the shares of Class A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company completes a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the Warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. As of March 31, 2021, there were Placement Warrants outstanding. At December 31, 2020 there were Placement Warrants outstanding. The Placement Warrants are identical to the Public Warrants underlying the Units sold in the IPO, except that the Placement Warrants and the Class A common stock issuable upon the exercise of the Placement Warrants will not be transferable, assignable or saleable until days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Placement Warrants will be non-redeemable

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 10. FAIR VALUE MEASUREMENTS At March 31, 2021, assets held in the Trust Account were comprised of $175,003,740 in money market funds which are invested primarily in U.S. Treasury Securities. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at March 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. Level March 31, 2021 Assets: Marketable securities held in Trust Account 1 $ 175,003,740 Liabilities: Warrant liability – Public Warrants 1 $ 3,558,333 Warrant liability – Placement Warrants 3 $ 116,267 The Warrants were accounted for as liabilities in accordance with ASC 815-40 The Public Warrants were initially valued using a Monte Carlo Simulation, and the Placement Warrants were valued using a Black-Scholes option pricing model (“Black-Scholes”), both of which are considered to be Level 3 fair value measurements. The primary unobservable input utilized in determining the fair value of the Placement Warrants is the expected volatility of the Company’s common stock. The expected volatility of the Company’s common stock was determined based on the implied volatility of the Public Warrants. For periods subsequent to the detachment of the Warrants from the Units, the close price of the Public Warrants was used as the fair value as of each relevant date. The key inputs utilized in the Monte Carlo simulation model for the Public Warrants and Black-Scholes for the Placement Warrants are as follows: January 12, 2021 (Initial Measurement) March 31, 2021 Public Placement Placement Input Warrants Warrants Warrants Stock Price $ 10.32 $ 10.32 $ 9.75 Exercise Price $ 11.50 $ 11.50 $ 11.50 Volatility 12.5 % 12.5 % 12.5 % Term (years) 5.00 5.00 5.00 Dividend Yield 0.00 0.00 % 0.00 % Risk Free Rate 0.50 % 0.09 % 0.92 % The following presents the changes in the fair value of warrant liabilities: Placement Warrants Public Warrants Warrant Liabilities Fair value as of January 1, 2021 $ — $ — $ — Initial measurement on January 12, 2021 130,800 4,200,000 4,330,800 Change in valuation inputs or other assumptions (14,533 ) (641,667 ) (656,200 ) Fair value as of March 31, 2021 $ 116,267 $ 3,558,333 $ 3,674,600 Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement during the three months ended March 31, 2021 was approximately $3.6 million.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 12. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, other than the following paragraphs, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. On May 26, 2021, the Company entered into the Merger Agreement by and among the Company, Merger Sub, a wholly-owned subsidiary of the Company, and eFFECTOR. Pursuant to the terms and conditions of the Merger Agreement, upon the closing, Merger Sub will merge with and into eFFECTOR with eFFECTOR surviving the Merger as a wholly-owned subsidiary of the Company. The Board of Directors of the Company has unanimously approved the Merger and resolved to recommend approval of the Merger Agreement to the stockholders of the Company. Consummation of the Merger is subject to approval by the Company’s stockholders and the satisfaction or waiver of certain other customary closing conditions. Upon the consummation of the Merger, the Company will be renamed “eFFECTOR Therapeutics, Inc.” eFFECTOR is a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors for the treatment of cancer. In connection with the Merger, the Company has entered into the Subscription Agreements with certain parties for a fully committed $60 million financing of Company common stock to be issued at $10.00 per share. The obligations to consummate the transactions contemplated by the Subscription Agreements are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Merger Agreement.	NOTE 8 — SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Other than the Company’s IPO and related transactions, as described in these financial statements, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q S-X The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s prospectus for its IPO as filed with the SEC on January 7, 2021. The interim results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future periods.	Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
Use of Estimates	Use of Estimates The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liability. Accordingly, the actual results could differ significantly from those estimates.	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2021 and December 31, 2020.	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2020.
Deferred Offering Costs		Deferred Offering Costs Deferred offering costs consisted of legal, accounting and other expenses incurred through the balance sheet date that were directly related to the IPO. On January 12, 2021, offering costs amounting to $10,097,226 were charged to stockholder’s equity upon the completion of the IPO (see Note 1). As of December 31, 2020, there were $177,937 of deferred offering costs recorded in the accompanying balance sheet.
Marketable Securities Held in Trust Account	Marketable Securities Held in Trust Account At March 31, 2021, substantially all of the assets held in the Trust Account were invested in Morgan Stanley’s Institution Liquid Treasury Securities Portfolio. The fund invests in U.S. Treasury obligation with maturities not to exceeding 397
Offering Costs	Offering Costs Offering costs, consisting of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the IPO, amounting to approximately $9,800,000 were charged to stockholders’ equity upon the completion of the IPO. For the three months ended March 31, 2021, approximately $242,000 of costs are included in transaction costs incurred in connection with warrant liabilities in the unaudited condensed statement of operations.
Class A common Stock Subject to Possible Redemption	Class A Common Stock Subject to Possible Redemption The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s Class A common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at March 31, 2021, 16,133,613 shares of Class A common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the condensed balance sheet.
Warrant Liability	Warrant Liability The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in non-cash are valued using a closed form Black-Scholes model.
Income Taxes	Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of March 31, 2021, the Company had a deferred tax asset of approximately $77,077, which had a full valuation allowance recorded against it The Company’s deferred tax assets were deemed to be de minimis Current taxable income primarily consists of interest earned on the Trust Account. The Company’s general and administrative costs are generally considered start-up start-up ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were The Company may be subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception.	Income Taxes The Company complies with the accounting and reporting requirements of Accounting Standards Codification (“ASC”) Topic 740 “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not The Company may be subject to potential examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and city tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since inception. The provision for income taxes was deemed to be de minimis for the period from October 2, 2020 (inception) through December 31, 2020. As of December 31, 2020, deferred taxes were de minimis.
Net income per Share of Common Stock	Net income per Share of Common Stock Net income per share is computed by dividing net income by the weighted average number of shares of common stock outstanding for the period. The Company has not considered the effect of warrants sold in the IPO and private placement to purchase 6,015,000 shares of Class A common stock in the calculation of diluted net income per share, since the exercise price of the warrants was above the average market price for the period. The condensed statement of operations includes a presentation of income per share of common stock subject to possible redemption in a manner similar to the two-class non-redeemable non-redeemable non-redeemable The following table reflects the calculation of basic and diluted net income per share of common stock (in dollars, except per share amounts): Three Months Ended March 31, 2021 Redeemable Class A Common Stock Numerator: Earnings allocable to Redeemable Class A common stock Interest income $ 3,740 Income and franchise tax (3,740 ) Net Income — Denominator: Weighted average Redeemable Class A common stock Redeemable Class A common stock, Basic and Diluted 17,500,000 Basic and diluted income per share, Class A redeemable common stock $ — Non-redeemable Numerator: Net Income minus redeemable net income Net income $ 48,837 Redeemable net income — Non-redeemable 48,837 Denominator: Weighted average Non-Redeemable Non-redeemable 4,922,417 Basic and diluted net income per share, Class A and Class B non-redeemable $ 0.01	Net Loss Per Common Share Net loss per share of common stock is computed by dividing net loss by the weighted average number of common shares outstanding during the period, excluding shares of common stock subject to forfeiture. Weighted average shares were reduced for the effect of an aggregate of 573,750 shares of Class B common stock that are subject to forfeiture by the Sponsor if the over-allotment option is not exercised by the underwriter (see Note 5). At December 31, 2020, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the period presented.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on such account.	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation insurance limits of $250,000. The Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, Fair Value Measurement, approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the Company’s balance sheet, primarily due to their short-term nature.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Recent Accounting Standards	Recent Accounting Standards In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2020-06, 470-20) 815-40) 2020-06”) 2020-06 2020-06 if-converted 2020-06 2020-06	Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of basic and diluted net income	The following table reflects the calculation of basic and diluted net income per share of common stock (in dollars, except per share amounts): Three Months Ended March 31, 2021 Redeemable Class A Common Stock Numerator: Earnings allocable to Redeemable Class A common stock Interest income $ 3,740 Income and franchise tax (3,740 ) Net Income — Denominator: Weighted average Redeemable Class A common stock Redeemable Class A common stock, Basic and Diluted 17,500,000 Basic and diluted income per share, Class A redeemable common stock $ — Non-redeemable Numerator: Net Income minus redeemable net income Net income $ 48,837 Redeemable net income — Non-redeemable 48,837 Denominator: Weighted average Non-Redeemable Non-redeemable 4,922,417 Basic and diluted net income per share, Class A and Class B non-redeemable $ 0.01

Restatement of Previously Iss_2

Restatement of Previously Issued Financial Statement (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Changes and Error Corrections [Abstract]
Summary of restatement of balance sheet	The Company’s accounting for the Warrants as components of equity instead of as derivative liabilities did not have any effect on the previously reported investments held in trust or cash. As Previously Reported Restatement As Restated Balance sheet as of January 12, 2021 (audited) Warrant Liability – Public Warrants $ — $ 4,200,000 $ 4,200,000 Warrant Liability – Placement Warrants — 130,800 130,800 Total Warrant Liabilities — 4,330,800 4,330,800 Class A Common Stock Subject to Possible Redemption 165,376,070 (4,330,800 ) 161,045,270 Class A Common Stock 151 44 195 Additional Paid-in 5,001,101 242,289 5,243,390 Accumulated Deficit (1,698 ) (242,333 ) (244,031 ) Number of Class A Common Stock Subject to Possible Redemptio n 16,537,607 (433,080 ) 16,104,527

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Summary of assets and liabilities measured at fair value on a recurring basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at March 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. Level March 31, 2021 Assets: Marketable securities held in Trust Account 1 $ 175,003,740 Liabilities: Warrant liability – Public Warrants 1 $ 3,558,333 Warrant liability – Placement Warrants 3 $ 116,267
Summary of fair value measurements inputs	The key inputs utilized in the Monte Carlo simulation model for the Public Warrants and Black-Scholes for the Placement Warrants are as follows: January 12, 2021 (Initial Measurement) March 31, 2021 Public Placement Placement Input Warrants Warrants Warrants Stock Price $ 10.32 $ 10.32 $ 9.75 Exercise Price $ 11.50 $ 11.50 $ 11.50 Volatility 12.5 % 12.5 % 12.5 % Term (years) 5.00 5.00 5.00 Dividend Yield 0.00 0.00 % 0.00 % Risk Free Rate 0.50 % 0.09 % 0.92 %
Summary of change in fair value of derivative warrant liabilities	The following presents the changes in the fair value of warrant liabilities: Placement Warrants Public Warrants Warrant Liabilities Fair value as of January 1, 2021 $ — $ — $ — Initial measurement on January 12, 2021 130,800 4,200,000 4,330,800 Change in valuation inputs or other assumptions (14,533 ) (641,667 ) (656,200 ) Fair value as of March 31, 2021 $ 116,267 $ 3,558,333 $ 3,674,600

Description of Organization A_2

Description of Organization And Business Operations - Additional Information (Detail) - USD ($)	May 26, 2021	Jan. 12, 2021	Mar. 31, 2021	Dec. 31, 2020
Organization consolidation and presentation of financial statements [Line Items]
Share price per share	$ 10		$ 10
Proceeds from issuance of IPO			$ 171,940,000
Proceeds from sale of Private Placement Units			5,450,000
Payment to acquire restricted investments			$ 175,000,000
Restricted investments term			185 days
Percentage of public shares to be redeemed on non completion of business combination			100.00%	100.00%
Lock in period for redemption of public shares after closing of IPO			24 months	24 months
Interest to pay dissolution expenses			$ 100,000	$ 100,000
Percentage of redeemable outstanding Public Shares held in the Trust Account			100.00%	100.00%
Minimum networth to effect business combination			$ 5,000,001
Stock Issued During Period, Shares, Issued for Services	6,000,000
Common Stock [Member]
Organization consolidation and presentation of financial statements [Line Items]
Finance Cost	$ 60,000,000		$ 60,000,000
eFFECTOR Therapeutics Inc [Member]
Organization consolidation and presentation of financial statements [Line Items]
Number of shares used to derive Exchange Ratio	34,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,000,000
Sponsor
Organization consolidation and presentation of financial statements [Line Items]
Percentage of voting interests acquired				25.00%
Sponsor | Share Price Equals or Exceeds To USD 20.00
Organization consolidation and presentation of financial statements [Line Items]
Share transfer, trigger price, price per share			$ 12
Number of consecutive trading days for determining share price			20 days
Number of trading days for determining share price			30 days
Class A Common stock | Common Stock [Member]
Organization consolidation and presentation of financial statements [Line Items]
Stock issued during period, shares, new issues			17,500,000
Class A Common stock | Sponsor | eFFECTOR Therapeutics Inc [Member] | Share Price Equals or Exceeds To USD 20.00
Organization consolidation and presentation of financial statements [Line Items]
Share transfer, trigger price, price per share			$ 20
Number of consecutive trading days for determining share price			20 days
Number of trading days for determining share price			30 days
Public Shares
Organization consolidation and presentation of financial statements [Line Items]
Share price per share			$ 10	$ 10
Maximum | eFFECTOR Therapeutics Inc [Member]
Organization consolidation and presentation of financial statements [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			$ 100,000,000
Maximum | Sponsor | Share Price Equals or Exceeds To USD 20.00
Organization consolidation and presentation of financial statements [Line Items]
Number of trading days for determining share price			90 days
Minimum
Organization consolidation and presentation of financial statements [Line Items]
Percentage of fair market value of target business to asset held in trust account			80.00%	80.00%
Percentage of voting interests acquired			50.00%	50.00%
Net tangible assets required for consummation of business combination			$ 5,000,001	$ 5,000,001
Percentage of redeeming shares of public shares sold in Initial Public Offering			20.00%	20.00%
IPO
Organization consolidation and presentation of financial statements [Line Items]
Stock issued during period, shares, new issues			15,300,000	15,300,000
Transaction costs			$ 10,097,226	$ 10,097,226
Payments for underwriting expense			3,060,000	3,060,000
Deferred underwriting commissions payable noncurrent			6,565,000	6,565,000
Other offering costs			472,226	472,226
Payment to acquire restricted investments			$ 175,000,000	$ 175,000,000
IPO | Class A Common stock
Organization consolidation and presentation of financial statements [Line Items]
Stock issued during period, shares, new issues		17,500,000		17,500,000
Share price per share		$ 10		$ 10
Proceeds from issuance of IPO		$ 175,000,000
Over-Allotment Option | Class A Common stock
Organization consolidation and presentation of financial statements [Line Items]
Stock issued during period, shares, new issues		2,200,000		2,200,000
Private Placement Warrants | Sponsor
Organization consolidation and presentation of financial statements [Line Items]
Class of warrants and rights issued during the period			545,000	545,000
Class of warrants and rights issued, price per warrant			$ 10	$ 10
Proceeds from sale of Private Placement Units			$ 5,450,000	$ 5,450,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Basic And Diluted Net Income (Detail) - USD ($)		3 Months Ended
		Mar. 31, 2021	Dec. 31, 2020
Numerator:
Net income		$ 48,837	$ (2,006)
Denominator:
Non-redeemable Class A and B common stock, Basic and Diluted	[1],[2]		3,961,250
Basic and diluted net income per share, Class A and Class B non-redeemable common stock			$ 0
Redeemable Class A Common Stock
Numerator:
Interest income		3,740
Income and franchise tax		(3,740)
Net income		$ 0
Denominator:
Non-redeemable Class A and B common stock, Basic and Diluted		17,500,000
Basic and diluted net income per share, Class A and Class B non-redeemable common stock		$ 0
Non Redeemable Class A and Class B Common Stock
Numerator:
Net income		$ 48,837
Redeemable net income		0
Non-redeemable net income		$ 48,837
Denominator:
Non-redeemable Class A and B common stock, Basic and Diluted		4,922,417
Basic and diluted net income per share, Class A and Class B non-redeemable common stock		$ 0.01
[1]	Excludes up to 573,750 shares of Class B common stock subject to forfeiture if the overallotment option is not exercised in full or in part by the underwriters. Due to the underwriter’s partial exercise of the over-allotment on January 11, 2021, the Sponsor forfeited 23,750 shares of Class B common stock resulting in 4,511,250 Founder Shares outstanding.
[2]	The Company effected a stock dividend on January 7, 2021 of 1.17259212 shares of Class B common stock for each share of Class B common stock outstanding prior to the dividend, resulting in an aggregate of 4,535,000 shares of Class B common stock outstanding. All share and per share amounts have been retroactively restated to reflect the stock dividend (see Note 5).

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Jan. 12, 2021	Mar. 31, 2021	Dec. 31, 2020
Cash Equivalents		$ 0	$ 0
Deferred tax asset		77,077
Income tax expense (benefit)		$ 0
Effective income tax rate reconciliation, percent		0.00%
Unrecognized tax benefits		$ 0	0
Accrued for interest and penalties		0	0
Federal depository insurance coverage		250,000	250,000
Transaction costs allocated to warrant liabilities		242,333
Deferred offering costs non current		$ 0	$ 177,937
Warrant
Antidilutive securities excluded from computation of earnings per share, amount		6,015,000
IPO
Offering costs	$ 10,097,226	$ 9,800,000
Class A Common stock
Temporary equity shares outstanding		16,133,613	0
Class B Common Stock
Number of shares forfeited during the period			573,750

Restatement of Previously Iss_3

Restatement of Previously Issued Financial Statement - Summary of Restatement of Balance Sheet (Detail) - USD ($)	Mar. 31, 2021	Jan. 12, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities	$ 3,674,600		$ 0
Additional Paid-in Capital	4,952,534		24,546
Accumulated Deficit	46,831		(2,006)
Class A Common stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Class A Common Stock	$ 191		$ 0
Number of Class A Common Stock Subject to Possible Redemption	16,133,613		0
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities		$ 0
Class A Common Stock Subject to Possible Redemption		165,376,070
Additional Paid-in Capital		5,001,101
Accumulated Deficit		$ (1,698)
Number of Class A Common Stock Subject to Possible Redemption		16,537,607
As Previously Reported | Public Warrants
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities		$ 0
As Previously Reported | Placement Warrants
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities		0
As Previously Reported | Class A Common stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Class A Common Stock		151
Restatement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities		4,330,800
Class A Common Stock Subject to Possible Redemption		(4,330,800)
Additional Paid-in Capital		242,289
Accumulated Deficit		$ (242,333)
Number of Class A Common Stock Subject to Possible Redemption		(433,080)
Restatement | Public Warrants
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities		$ 4,200,000
Restatement | Placement Warrants
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities		130,800
Restatement | Class A Common stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Class A Common Stock		44
As Restated
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities		4,330,800
Class A Common Stock Subject to Possible Redemption		161,045,270
Additional Paid-in Capital		5,243,390
Accumulated Deficit		$ (244,031)
Number of Class A Common Stock Subject to Possible Redemption		16,104,527
As Restated | Public Warrants
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities		$ 4,200,000
As Restated | Placement Warrants
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrant liabilities		130,800
As Restated | Class A Common stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Class A Common Stock		$ 195

Restatement of Previously Iss_4

Restatement of Previously Issued Financial Statement - Additional Information (Detail)	Mar. 31, 2021
Accounting Changes and Error Corrections [Abstract]
Percentage of outstanding single class of stock accepted by holders in warrant agreement	50.00%

Public Offering - Additional In

Public Offering - Additional Information (Detail) - $ / shares	Jan. 12, 2021	Mar. 31, 2021	Dec. 31, 2020	May 26, 2021
Share price per share		$ 10		$ 10
Class A Common stock
Exercise price of warrants		$ 9.20	$ 9.20
Class A Common stock | Public Warrants
Number of shares of common stock issuable on exercise of each warrant		1	1
Exercise price of warrants		$ 11.50	$ 11.50
IPO
Stock issued during period shares		15,300,000	15,300,000
IPO | Public Warrants
Stock issued during period shares		17,500,000
IPO | Class A Common stock
Stock issued during period shares	17,500,000		17,500,000
Share price per share	$ 10		$ 10
Over-Allotment Option | Class A Common stock
Stock issued during period shares	2,200,000		2,200,000

Private Placement - Additional

Private Placement - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Proceeds from sale of Private Placement Units	$ 5,450,000
Class A Common stock
Exercise price of warrants	$ 9.20	$ 9.20
Private Placement Warrants | Class A Common stock
Exercise price of warrants	$ 11.50	$ 11.50
Sponsor | Private Placement Warrants
Class of warrants and rights issued during the period	545,000	545,000
Class of warrants and rights issued, price per warrant	$ 10	$ 10
Proceeds from sale of Private Placement Units	$ 5,450,000	$ 5,450,000
Number of shares of common stock issuable on exercise of each warrant	1	1

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Jan. 12, 2021	Oct. 31, 2020	Dec. 31, 2020	Mar. 31, 2021	Dec. 31, 2020	Jan. 11, 2021	Oct. 06, 2020
Proceeds from related party debt					$ 55,000
Related party transaction, terms of agreement					The Insiders have agreed not to transfer, assign or sell any of their Founder Shares (except to permitted transferees) until (i) with respect to 25% of such shares, upon consummation of the Company’s initial Business Combination, (ii) with respect to 25% of such shares, when the closing price of the Class A common stock exceeds $12.00 for any 20 trading days within a 30-trading day period following the consummation of a Business Combination, (iii) with respect to 25% of such shares, when the closing price of the Class A common stock exceeds $13.50 for any 20 trading days within a 30-trading day period following the consummation of a Business Combination and (iv) with respect to 25% of such shares, when the closing price of the Class A common stock exceeds $17.00 for any 20 trading days within a 30-trading day period
Working Capital Loan
Due to Related Parties			$ 0	$ 0	$ 0
Debt instrument convertible into warrants			$ 1,500,000	$ 1,500,000	$ 1,500,000
Debt instrument conversion price			$ 10	$ 10	$ 10
Sponsor
Business acquisition, voting interest percentage			25.00%		25.00%
Sponsor | Promissory Note
Debt instrument, face amount							$ 300,000
Proceeds from related party debt			$ 60,375	$ 0
Debt instrument interest rate				0.00%
Sponsor | Share Price Equals or Exceeds To USD Twelve
Share transfer, trigger price, price per share			$ 12		$ 12
Number of consecutive trading days for determining share price					20 days
Number of trading days for determining share price					30 days
Business acquisition, voting interest percentage			25.00%		25.00%
Sponsor | Share Price Equals or Exceeds To USD Thirteen Point Five
Share transfer, trigger price, price per share			$ 13.50		$ 13.50
Number of consecutive trading days for determining share price					20 days
Number of trading days for determining share price					30 days
Business acquisition, voting interest percentage			25.00%		25.00%
Sponsor | Share Price Equals or Exceeds To seventeen
Share transfer, trigger price, price per share			$ 17		$ 17
Number of consecutive trading days for determining share price					20 days
Number of trading days for determining share price					30 days
Business acquisition, voting interest percentage			25.00%		25.00%
Sponsor | Share Price Equals or Exceeds To USD 20.00
Share transfer, trigger price, price per share				$ 12
Lock in period for redemption of public shares after closing of merger				270 days
Number of consecutive trading days for determining share price				20 days
Number of trading days for determining share price				30 days
Sponsor | Share Price Equals or Exceeds To USD 20.00 | Maximum
Number of trading days for determining share price				90 days
Sponsor | Founder Shares
Shares issued, shares, share-based payment arrangement, forfeited		4,535,000
Sponsor | Accounts Payable and Accrued Liabilities
Related party transaction, amounts of transaction				$ 15,015
Sponsor | Office Space Administrative And Support Services
Related party transaction, amounts of transaction	$ 10,000
Class B Common Stock
Proceeds from issuance of common stock					$ 25,000
Class B Common Stock | Founder Shares
Common stock, dividends, per share, declared		$ 1.17259212
Temporary equity shares outstanding			4,511,250	4,511,250	4,511,250	4,511,250
Class B Common Stock | Sponsor | Founder Shares
Stock issued during period, shares, new issues		3,867,500
Proceeds from issuance of common stock		$ 25,000
Shares issued, shares, share-based payment arrangement, forfeited		23,750
Temporary equity shares outstanding		4,511,250

Commitments and Contingencies

Commitments and Contingencies - Additional Information (Detail) - USD ($)	May 26, 2021	Mar. 31, 2021	Dec. 31, 2020
Commitments [Line Items]
Stock issued during period, value, new issues		$ 160,945,107
Stock Issued During Period, Shares, Issued for Services	6,000,000
Share price per share	$ 10	$ 10
Common Stock
Commitments [Line Items]
Finance cost	$ 60,000,000	$ 60,000,000
IPO
Commitments [Line Items]
Percentage of deferred underwriting fee		3.50%	3.50%
Stock issued during period, shares, new issues		15,300,000	15,300,000
Stock issued during period, value, new issues		$ 5,355,000	$ 5,355,000
Over-Allotment Option
Commitments [Line Items]
Stock Repurchased During Period, Shares		2,200,000	2,200,000
Number of shares forfeited during the period		95,000	95,000
Percentage of deferred underwriting fee		5.50%	5.50%
Stock issued during period, value, new issues		$ 1,210,000	$ 1,210,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - $ / shares	Jan. 11, 2021	Mar. 31, 2021	Dec. 31, 2020	May 26, 2021	Jan. 07, 2021
Preferred stock, shares authorized		1,000,000	1,000,000
Preferred stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Share price		$ 10		$ 10
Public Warrants
Warrants outstanding		5,833,333	0
Warrants exercisable term from the date of completion of business combination		30 days	30 days
Warrants exercisable term from the closing of IPO		12 months	12 months
Warrants and rights outstanding, term		5 years	5 years
Minimum lock In period to become effective after the closing of the initial business combination		60 days	60 days
Minimum lock In period for SEC registration from date of business combination		60 days	60 days
Class of warrants, redemption price per unit		$ 0.01	$ 0.01
Class of warrants, redemption notice period		30 days	30 days
Public Warrants | Share Price Equal or Exceeds Eighteen Rupees Per Dollar [Member]
Share price		$ 18	$ 18
Number of consecutive trading days for determining share price		20 days	20 days
Number of trading days for determining share price		30 days	30 days
Private Placement Warrants
Warrants outstanding		181,667	0
Over-Allotment Option
Number of shares forfeited during the period		95,000	95,000
Class A Common stock
Common stock, shares authorized		100,000,000	100,000,000
Common stock, par value		$ 0.0001	$ 0.0001
Common stock, voting rights per share		one
Common stock, shares issued		1,911,387	0
Common stock, shares outstanding		1,911,387	0
Temporary equity shares outstanding		16,133,613	0
Stock conversion basis		Holders of Class A common stock are entitled to one vote for each share.	Holders of Class A common stock are entitled to one vote for each share.
Exercise price of warrants		$ 9.20	$ 9.20
Class A Common stock | Share Price Equal or Exceeds Eighteen Rupees Per Dollar [Member]
Share redemption trigger price		$ 18	$ 18
Class of warrant or right exercise price adjustment percentage higher of market value		180.00%	180.00%
Class A Common stock | Share Price Equal or Less Nine point Two Rupees Per Dollar [Member]
Share redemption trigger price		$ 9.20	$ 9.20
Class of warrant or right exercise price adjustment percentage higher of market value		115.00%	115.00%
Class A Common stock | Public Warrants
Exercise price of warrants		$ 11.50	$ 11.50
Minimum percentage gross proceeds required from issuance of equity		50.00%	50.00%
Class of warrant or right minimum notice period for redemption		20 days	20 days
Class A Common stock | Private Placement Warrants
Minimum lock In period to become effective after the closing of the initial business combination		30 days	30 days
Exercise price of warrants		$ 11.50	$ 11.50
Class A Common stock | Founder Shares
Common stock, threshold percentage on conversion of shares		2.00%	2.00%
Class B Common Stock
Common stock, shares authorized		10,000,000	10,000,000
Common stock, par value		$ 0.0001	$ 0.0001
Common stock, voting rights per share		one
Common stock, shares issued		4,511,250	4,535,000
Common stock, shares outstanding		4,511,250	4,535,000		4,535,000
Percentage of ownership held by initial shareholders	20.00%	20.00%
Stock conversion basis		Holders of the Company’s Class B common stock are entitled to one vote for each share of common stock.	Holders of the Company’s Class B common stock are entitled to one vote for each common share.
Class B Common Stock | Founder Shares
Temporary equity shares outstanding	4,511,250	4,511,250	4,511,250
Class B Common Stock | Over-Allotment Option
Number of shares forfeited during the period	23,750	23,750

Warrants - Additional Informati

Warrants - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	May 26, 2021
Share price	$ 10		$ 10
Public Warrants
Warrants and rights outstanding	5,833,333	0
Warrants exercisable term from the date of completion of business combination	30 days	30 days
Warrants exercisable term from the closing of IPO	12 months	12 months
Warrants and rights outstanding, term	5 years	5 years
Minimum lock In period to become effective after the closing of the initial business combination	60 days	60 days
Minimum lock In period for SEC registration from date of business combination	60 days	60 days
Class of warrants, redemption price per unit	$ 0.01	$ 0.01
Class of warrants, redemption notice period	30 days	30 days
Public Warrants | Share Price Equal or Exceeds Eighteen Rupees Per Dollar
Share price	$ 18	$ 18
Number of consecutive trading days for determining share price	20 days	20 days
Number of trading days for determining share price	30 days	30 days
Private Placement Warrants
Warrants and rights outstanding	181,667	0
Class A Common stock
Exercise price of warrants	$ 9.20	$ 9.20
Class A Common stock | Share Price Equal or Exceeds Eighteen Rupees Per Dollar
Share redemption trigger price	$ 18	$ 18
Class of warrant or right exercise price adjustment percentage higher of market value	180.00%	180.00%
Class A Common stock | Share Price Equal or Less Nine point Two Rupees Per Dollar
Share redemption trigger price	$ 9.20	$ 9.20
Class of warrant or right exercise price adjustment percentage higher of market value	115.00%	115.00%
Class A Common stock | Public Warrants
Exercise price of warrants	$ 11.50	$ 11.50
Minimum percentage gross proceeds required from issuance of equity	50.00%	50.00%
Class of warrant or right minimum notice period for redemption	20 days	20 days
Class A Common stock | Private Placement Warrants
Minimum lock In period to become effective after the closing of the initial business combination	30 days	30 days
Exercise price of warrants	$ 11.50	$ 11.50

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets And Liabilities Measured At Fair Value On Recurring Basis (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Liabilities:
Warrant liability	$ 3,674,600	$ 0
Fair Value, Recurring | Fair Value Inputs Level 1 | Public Warrants
Liabilities:
Warrant liability	3,558,333
Fair Value, Recurring | Fair Value Inputs Level 1 | Marketable Securities Held In Trust
Assets:
Marketable securities held in Trust Account	175,003,740
Fair Value, Recurring | Fair Value Inputs Level 3 | Placement Warrants
Liabilities:
Warrant liability	$ 116,267

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Fair Value Measurements Inputs (Detail)	Mar. 31, 2021$ / sharesyr	Jan. 12, 2021$ / sharesyr
Stock Price | Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input		10.32
Stock Price | Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input	9.75	10.32
Exercise price | Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input		11.50
Exercise price | Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input	11.50	11.50
Volatility | Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input		12.5
Volatility | Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input	12.5	12.5
Term (years) | Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input | yr		5
Term (years) | Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input | yr	5	5
Dividend Yield | Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input		0
Dividend Yield | Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input	0	0
Risk Free Rate | Public Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input		0.50
Risk Free Rate | Placement Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement Input	0.92	0.09

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Change In Fair Value of Derivative Warrant Liabilities (Detail)	3 Months Ended
	Mar. 31, 2021USD ($)
Placement Warrants
Class of Warrant or Right [Line Items]
Fair value, Beginning Balance
Initial measurement on January 12, 2021	130,800
Change in valuation inputs or other assumptions	(14,533)
Fair value, Ending Balance	116,267
Public Warrants
Class of Warrant or Right [Line Items]
Fair value, Beginning Balance
Initial measurement on January 12, 2021	4,200,000
Change in valuation inputs or other assumptions	(641,667)
Fair value, Ending Balance	3,558,333
Warrant Liabilities
Class of Warrant or Right [Line Items]
Fair value, Beginning Balance
Initial measurement on January 12, 2021	4,330,800
Change in valuation inputs or other assumptions	(656,200)
Fair value, Ending Balance	$ 3,674,600

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021USD ($)
Fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers, net	$ 3,600,000
Money Market Funds
Assets held in trust	$ 175,003,740

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	May 26, 2021	Mar. 31, 2021
Subsequent Event [Line Items]
Share price	$ 10	$ 10
Common Stock
Subsequent Event [Line Items]
Finance cost	$ 60,000,000	$ 60,000,000